Testimonials
What Our
Collaborators Say
Testimonials
Drug-induced liver injury (DILI) is a common finding in preclinical and clinical studies. The FDA scrutinizes data for any sign of DILI. False positive signals from AST/ALT can trigger significant program delays to investigate mechanism of action and confirm drug safety. I want a liver toxicity test with higher sensitivity and specificity.
Jay Stallons PhD DBAT
It’s hard to separate true drug safety signals from false ones with current tests. This harms clinical safety trial power. Liver toxicity screening is stuck in the ‘90s with very low data input. The current LFT is insufficent.
Julia Warren MD PhD
MPathy Bio’s focus on reduced false positives in toxicity biomarkers is well aligned with the needs of our cohort studies on the extension of health and lifespan in dogs. Having high sensitivity and specificity tests for therapy-induced liver toxicity would be superior to the relatively simplistic status quo that can be inaccurate due to a transient or benign biological state in the dog, such as dehydration.
Daniel Promislow, head of the Dog Aging Project